

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
CONVEYING PARTY DATA	
Name	Execution Date
Haymarket Financial LLP, as Security Agent	06/12/2012
RECEIVING PARTY DATA	
Name:	EUSA Pharma (USA), Inc.
Street Address:	One Summit Square, 1717 Langhorne Newtown Road, Suite 201
City:	Langhorne
State/Country:	PENNSYLVANIA
Postal Code:	19047
PROPERTY NUMBERS Total: 9	
Property Type	Number
Patent Number:	5162504
Patent Number:	5763202
Patent Number:	5993785
Patent Number:	6387352
Patent Number:	4898724
Patent Number:	5066478
Patent Number:	5300279
Patent Number:	4937333
Patent Number:	5714604
CORRESPONDENCE DATA	
Fax Number:	(415)693-2222
Phone:	4156932440
Email:	crhem@cooley.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Cooley LLP

CH \$360.00 5162504

Address Line 1: 101 California Street, 5th Floor  
Address Line 4: San Francisco, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER: 317094-106 JAZZ

NAME OF SUBMITTER: C. Rhem

Total Attachments: 7  
source=US - Release of Patents#page1.tif  
source=US - Release of Patents#page2.tif  
source=US - Release of Patents#page3.tif  
source=US - Release of Patents#page4.tif  
source=US - Release of Patents#page5.tif  
source=US - Release of Patents#page6.tif  
source=US - Release of Patents#page7.tif

**RELEASE OF SECURITY INTEREST  
IN PATENT COLLATERAL**

This RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (this "Release") is made as of June 12, 2012, by Haymarket Financial LLP in its capacity as security agent and trustee for the Secured Parties (in such capacity, the "Security Agent"), in favor of EUSA Pharma, Inc., EUSA Pharma (Holdings), Inc. and EUSA Pharma (USA), Inc. (collectively, the "Grantors"). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Patent Security Agreement (as defined below), or if not defined therein, in the Pledge and Security Agreement (as defined below).

**WITNESSETH:**

**WHEREAS**, Grantors are a party to that certain Pledge and Security Agreement, dated as of April 20, 2011, by and among the Grantors and the other grantors party thereto and the Security Agent (the "Pledge and Security Agreement") pursuant to which the Grantors executed and delivered that certain Patent Security Agreement, dated as of April 20, 2011 (the "Patent Security Agreement");

**WHEREAS**, pursuant to the Patent Security Agreement, each of the Grantors granted to the Security Agent, for the benefit of the Secured Parties, a security interest in and continuing lien on all of such Grantor's right, title and interest in, to and under the following, whether then owned or existing, or thereafter acquired, developed, created or arising and wherever located: all United States and foreign patents and certificates of invention, or similar industrial property rights, and applications for any of the foregoing, including, but not limited to: (i) each patent and patent application listed on Schedule A, (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals, and reexaminations thereof, (iii) all patentable inventions and improvements thereto, (iv) the right to sue or otherwise recover for any past, present and future infringement or other violation thereof, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages, and proceeds of suit then or thereafter due and/or payable with respect thereto, and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world (collectively, the "Patent Collateral");

**WHEREAS**, the Patent Security Agreement was recorded with the United States Patent and Trademark Office at Reel 026213, Frame 0210 on May 2, 2011; and

**WHEREAS**, the Security Agent acknowledges full performance of the Secured Obligations and accordingly has agreed to release the grant of its security interest in and continuing lien on all of the Grantors' right, title, and interest in, to and under the Patent Collateral, and to reconvey any and all rights in the Patent Collateral to the Grantors;

**NOW THEREFORE**, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Security Agent hereby releases, relinquishes and discharges, with respect to each Grantor, all of its security interest in and continuing lien on all such Grantor's right, title, and interest in, to and under the Patent Collateral, and reassigns to such Grantor any and all right, title or interest it may have in such Patent Collateral, all without warranty or representation of any kind.

The Security Agent hereby authorizes the Grantors, or the Grantors' authorized representatives to: (a) record this Release with the United States Patent and Trademark Office and/or any other applicable governmental office or Agency, and (b) file UCC financing statement amendments with


the applicable filing office in order to memorialize the release of the lien on and security interest of the Security Agent in the Patent Collateral.

*[Signature page follows]*

IN WITNESS WHEREOF, the Security Agent has caused this Release to be duly executed by its duly authorized representative as of the day and year first above written.

Haymarket Financial LLP  
as Security Agent

By:



Name: *S. Deane*

Title: *Partner*

**SCHEDULE A**

**PATENTS AND PATENT APPLICATIONS**

<b>Grantor</b>	<b>Record Owner</b>	<b>Jurisdiction</b>	<b>Title of Patent</b>	<b>Patent Number</b>	<b>Issue Date</b>
EUSA Pharma (USA), Inc.	Cytogen	United States	Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and serum of Prostatic Cancer Patients	US 5,162,504	November 10, 1992
EUSA Pharma (USA), Inc.	Cytogen	Canada	Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and serum of Prostatic Cancer Patients	CA 1,339,607	December 30, 1997
EUSA Pharma (USA), Inc.	Cytogen	United States	Methods of detecting prostate carcinoma using a monoclonal antibody to a new antigenic marker in epithelial prostatic cells alone or with a monoclonal antibody to an antigen of LNCaP cells	US 5,763,202	June 9, 1998

**PATENT LICENSES**

Grantor	Description of Patent License	Patent Number of underlying Patent	Name of Licensor
EUSA Pharma (USA), Inc.	Mouthwash compositions	US 5,993,785	Erling Johansen & Thor Olsen
EUSA Pharma (USA), Inc.	Mouthwash compositions	US 6,387,352	Erling Johansen
EUSA Pharma (USA), Inc.	Mouthwash Comprising Calcium and Phosphate Ions in Supersaturated Solution	CA 2266409	Erling Johansen & Thor Olsen
EUSA Pharma (USA), Inc.	Mouthwash Comprising Calcium and Phosphate Ions in Supersaturated Solution	EP 0939613	Erling Johansen & Thor Olsen
EUSA Pharma (USA), Inc.	Compositions	GB 2329836	Erling Johansen & Thor Olsen
EUSA Pharma (USA), Inc.	Compositions	GB 2318977	Erling Johansen & Thor Olsen
EUSA Pharma (USA), Inc.	Gargle Comprising Calcium and Phosphate Ions in Supersaturated Solution	JP 03895388	Erling Johansen & Thor Olsen
EUSA Pharma (USA), Inc.	Gargle Comprising Calcium and Phosphate Ions in Supersaturated Solution	JP 20060043285	Erling Johansen & Thor Olsen
EUSA Pharma (USA), Inc.	Mouthwash Comprising Calcium and Phosphate Ions in Supersaturated Solution	NO 0313367	Erling Johansen & Thor Olsen
EUSA Pharma (USA), Inc.	Mouthwash Comprising Calcium and Phosphate Ions in Supersaturated Solution	ZA 9708361	Erling Johansen & Thor Olsen
EUSA Pharma (USA), Inc.	Organic amine phosphonic acid complexes for the treatment of calcific tumors	US 4898724	Dow Chemical
EUSA Pharma (USA), Inc.	Radio Labeled Organic	US	Dow Chemical

Inc.	Amine Phosphonic Acid Complexes for the Treatment of Calcific Tumors	5066478	
EUSA Pharma (USA), Inc.	Organic amine phosphonic acid complexes for the treatment of calcific tumors	US 5300279	Dow Chemical
EUSA Pharma (USA), Inc.	Method for purifying aminomethylenephosphonic acids for pharmaceutical use	US 4937333	Dow Chemical
EUSA Pharma (USA), Inc.	Process For the Preparation of Azamacrocyclic fr Acyclic Aminophosphonate Ester Derivatives	US 5714604	Dow Chemical
EUSA Pharma (USA), Inc.	Process For the Preparation of Azamacrocyclic fr Acyclic Aminophosphonate Ester Derivatives	332,902	Dow Chemical
EUSA Pharma (USA), Inc.	Radiopharmaceutical Formulations, their method of administration & Process of Preparation	319,952	Dow Chemical
EUSA Pharma (USA), Inc.	Radiopharmaceutical Formulations, their method of administration & Process of Preparation	527/91	Dow Chemical
EUSA Pharma (USA), Inc.	Radiopharmaceutical Formulations, their method of administration & Process of Preparation	9203064	Dow Chemical
EUSA Pharma (USA), Inc.	Radiopharmaceutical Formulations, their method of administration & Process of Preparation	26280	Dow Chemical
EUSA Pharma (USA), Inc.	Radiopharmaceutical Formulations, their method of administration & Process of Preparation	800/91	Dow Chemical
EUSA Pharma (USA), Inc.	Radiopharmaceutical Formulations, their method of administration & Process of Preparation	CA 2044812	Dow Chemical
EUSA Pharma (USA), Inc.	Process for Purifying Aminoethylencphosphonic Acids	CA 2020950	Dow Chemical



EUSA Pharma (USA), Inc.	Process for the Preparation of Azamacrocyclic or Acyclic Aminophosphonate Ester Derivatives	CA 2162170	Dow Chemical
----------------------------	--	---------------	--------------

---